ZA201902344B - Compounds and methods for activating tie2 signaling - Google Patents

Compounds and methods for activating tie2 signaling

Info

Publication number
ZA201902344B
ZA201902344B ZA2019/02344A ZA201902344A ZA201902344B ZA 201902344 B ZA201902344 B ZA 201902344B ZA 2019/02344 A ZA2019/02344 A ZA 2019/02344A ZA 201902344 A ZA201902344 A ZA 201902344A ZA 201902344 B ZA201902344 B ZA 201902344B
Authority
ZA
South Africa
Prior art keywords
compounds
methods
tie2 signaling
activating tie2
activating
Prior art date
Application number
ZA2019/02344A
Other languages
English (en)
Inventor
B Pandey Niranjan
Mirando Adam
S Popel Aleksander
J Green Jordan
Original Assignee
Asclepix Therapeutics Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asclepix Therapeutics Inc, Univ Johns Hopkins filed Critical Asclepix Therapeutics Inc
Publication of ZA201902344B publication Critical patent/ZA201902344B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA2019/02344A 2016-10-04 2019-04-12 Compounds and methods for activating tie2 signaling ZA201902344B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403786P 2016-10-04 2016-10-04
PCT/US2017/055055 WO2018067646A1 (en) 2016-10-04 2017-10-04 Compounds and methods for activating tie2 signaling

Publications (1)

Publication Number Publication Date
ZA201902344B true ZA201902344B (en) 2021-09-29

Family

ID=61832135

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/02344A ZA201902344B (en) 2016-10-04 2019-04-12 Compounds and methods for activating tie2 signaling

Country Status (14)

Country Link
US (1) US20190225670A1 (cg-RX-API-DMAC7.html)
EP (1) EP3522906B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019535651A (cg-RX-API-DMAC7.html)
KR (1) KR20190066040A (cg-RX-API-DMAC7.html)
CN (1) CN110177563A (cg-RX-API-DMAC7.html)
AU (1) AU2017339970A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019006735A2 (cg-RX-API-DMAC7.html)
CA (1) CA3038809A1 (cg-RX-API-DMAC7.html)
EA (1) EA201990868A1 (cg-RX-API-DMAC7.html)
IL (1) IL265694A (cg-RX-API-DMAC7.html)
MX (1) MX2019003895A (cg-RX-API-DMAC7.html)
SG (1) SG10202103032QA (cg-RX-API-DMAC7.html)
WO (1) WO2018067646A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902344B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
AU2018266690A1 (en) * 2017-05-08 2019-12-12 Asclepix Therapeutics, Inc. Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
KR20210146352A (ko) * 2019-03-26 2021-12-03 아스클리픽스 테라퓨틱스, 인크. 안구 질환 치료용 조성물 및 방법
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用
WO2024044745A2 (en) * 2022-08-26 2024-02-29 Asclepix Therapeutics, Inc. Formulations for intraocular delivery of peptides derived from type iv collagen
KR20240133892A (ko) * 2023-02-28 2024-09-05 주식회사 파멥신 전신 모세혈관 누출 증후군의 예방 또는 치료용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663053B2 (en) 1990-06-11 1995-09-28 Gilead Sciences, Inc. Nucleic acid ligands
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP1405911A1 (en) 1994-07-20 2004-04-07 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ATE320486T1 (de) 1999-05-05 2006-04-15 Phylogica Ltd Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten
AU4761100A (en) 1999-05-26 2000-12-18 Kalle Saksela Methods and materials for generating sh3 domains with tailored binding properties
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP2284270A3 (en) 2000-12-13 2012-07-25 Anaphore, Inc. Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
AU2003282724B2 (en) 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
WO2007033215A2 (en) * 2005-09-12 2007-03-22 The Johns Hopkins University Compositions having antiangiogenic activity and uses thereof
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
AR070032A1 (es) * 2007-11-09 2010-03-10 Genentech Inc Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1)
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
CN103495170A (zh) * 2009-07-07 2014-01-08 诺尔姆奥克西斯公司 使用肌醇三焦磷酸减少多药抗性的方法
EP2649095B1 (en) 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
EP2788473A4 (en) 2011-12-09 2015-11-11 Univ Johns Hopkins ARTIFICIAL ANTIGEN PRESENTING CELLS WITH DEFINED AND DYNAMIC FORM
CA2914764C (en) 2013-06-07 2021-10-26 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis-and lymphangiogenesis-dependent diseases

Also Published As

Publication number Publication date
EP3522906A4 (en) 2020-06-10
MX2019003895A (es) 2019-10-07
AU2017339970A1 (en) 2019-04-18
CN110177563A (zh) 2019-08-27
JP2019535651A (ja) 2019-12-12
BR112019006735A2 (pt) 2019-06-25
IL265694A (en) 2019-05-30
EA201990868A1 (ru) 2019-09-30
CA3038809A1 (en) 2018-04-12
US20190225670A1 (en) 2019-07-25
KR20190066040A (ko) 2019-06-12
EP3522906B1 (en) 2022-03-23
EP3522906A1 (en) 2019-08-14
WO2018067646A1 (en) 2018-04-12
SG10202103032QA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
ZA201904140B (en) Hybrid-srs combination signaling
ZA201902344B (en) Compounds and methods for activating tie2 signaling
GB2531419B (en) Clamping device
ZA201700466B (en) Signalling system
GB201405845D0 (en) Signalling system
LT3215147T (lt) Neurologinį poveikį mažinantys norketamino junginiai ir būdai
PL3855782T3 (pl) Układ sygnalizacji dla systemu bezprzewodowego
HUE046875T2 (hu) Technikák jelkiterjesztés jelzésére
IL251753B1 (en) Inaudible signal tone
GB201602563D0 (en) Signalling system
IL246617A0 (en) Establish means and methods for free grazing
PL3043111T3 (pl) Urządzenie sygnalizacyjne
IL259491A (en) Improved signaling device
GB201602571D0 (en) Signalling system
IL251107A0 (en) Compounds and methods
GB201608779D0 (en) Methods and compounds
EP3363002C0 (en) DIRECTION SIGNALING DEVICE
GB2550896B (en) Signalling system
GB201608776D0 (en) Methods and compounds
SG11201704664VA (en) Hydraulic lockdown
LU92833B1 (en) Clamping device
GB201416798D0 (en) Clamping arrangement
GB2551475B (en) Warning device
GB201612439D0 (en) Signalling apparatus and associated methods
HK40012579A (en) Compounds and methods for activating tie2 signaling